Results 131 to 140 of about 172,168 (267)

BCR: a new target in resistance mediated by BCR/ABL-315I?

open access: yes, 2016
Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the "gatekeeper" mutation T315I confers resistance against all approved TKIs, with the only exception ...
Mian AA   +5 more
core   +1 more source

Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S4 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

The interaction of P160 BCR with BCR-ABL gene products unique to Philadelphia chromosome leukemias

open access: yes, 1992
The BCR gene is involved in the pathogenesis of Philadelphia chromosome-positive (Ph$\sp1$) leukemias. Typically, the 5$\sp\prime$ portion of BCR on chromosome 22 becomes fused to a 5$\sp\prime$ truncated ABL gene from chromosome 9 resulting in a ...
Campbell, Martin Lee
core   +1 more source

Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints

open access: yesHaematologica, 2000
BACKGROUND AND OBJECTIVE: We further characterized a novel type of chimeric BCR-ABL mRNA transcript detected in a patient with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
G Martinelli   +9 more
doaj  

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

open access: yesCancer Cell, 2005
E. Weisberg   +20 more
semanticscholar   +1 more source

Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S3 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

Bcr: A conditional inhibitor of Bcr-Abl oncoprotein

open access: yes, 1999
Chronic myelogenous leukemia (CML) is characterized cytogenetically by the presence of the Philadelphia chromosome and clinically by the clonal expansion of the hematopoietic stem cells and the accumulation of large numbers of myeloid cells. Philadelphia
Wu, Yun
core   +1 more source

Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia

open access: yesBiomedical Technology
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong   +12 more
doaj   +1 more source

Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

open access: yes, 2008
Supplementary Fig. S1 from Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia ...
Ilene Galinsky (64265)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy